凤凰网港股|Cortexyme(CRTX)宣布提出新的临床前数据，将牙龈脓肿与磷脂酰-tau217水平的增加联系起来，磷脂酰-tau217是阿尔茨海默病的一个新兴生物标志物。这项研究及其关键的GAIN试验的新基线数据将由该公司在7月26日至30日于科罗拉多州丹佛举行的2021年阿尔茨海默氏症协会国际会议（AAIC）上公布，并以虚拟方式公布。除了演讲之外，Cortexyme公司还将主持一个企业赞助的研讨会，该研讨会与会议同时举行，题为 "找到阿尔茨海默病的根本原因，一个创新的、上游的疾病矫正方法"。
Cortexyme公司首席执行官、联合创始人兼主席Casey Lynch说："Cortexyme公司继续开展研究，验证并加强了牙龈蛋白酶假说和牙龈菌作为阿尔茨海默病致病因子的作用。GAIN试验的设计是以90%的力量来显示50%的疾病减缓，在Cortexyme寻求改变有效的阿尔茨海默氏症治疗模式时，它将读出疾病改变的黄金标准措施"。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.